Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the immunisation protects vulnerable infants

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine works by activating the mother’s body’s defences to produce defence proteins, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence suggesting that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine at the recommended time, whilst noting that protection can still occur even if given later in the third trimester.

• Nearly 85 per cent coverage when immunised 4 weeks before birth
• Antibodies from the mother transferred through placenta protect newborns from day one
• Coverage achievable with 2-week gap before early delivery
• Vaccination during third trimester still provides significant infant protection

Persuasive evidence from current research

The performance of the pregnancy RSV vaccine has been established through a comprehensive study conducted across England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that half-year window, providing robust and representative information of the vaccine’s real-world impact. The study’s findings have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scope of this study offers healthcare professionals and parents-to-be with confidence in the vaccine’s proven efficacy across diverse populations and circumstances.

The results paint a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This clear distinction underscores the vaccine’s critical role in preventing serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.

Study design and parameters

The research examined birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospital admissions. The large sample size and comprehensive nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than individual cases or limited subgroups.

The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology captured real-world outcomes rather than experimental conditions, providing tangible evidence of how the vaccine performs when delivered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.

Comprehending RSV and its dangers

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.

The infection causes deep inflammation in the lungs and airways, making it extremely challenging for infected babies to breathe and feed adequately. Parents frequently observe their babies fighting for breath, their chests heaving as they work to get enough air into their weakened respiratory system. Whilst the majority of babies get better with clinical support, a modest yet notable proportion perish from RSV complications each year, making prevention through vaccination a critical public health priority for protecting the youngest and most vulnerable individuals in the population.

• RSV produces inflammation in lungs, resulting in serious respiratory problems in babies
• Approximately half of infants contract the infection in their first few months of life
• Symptoms vary between mild colds to life-threatening chest infections needing hospital treatment
• Over 20,000 UK infants require serious hospital care for RSV annually
• A small number of babies succumb to RSV complications annually in the UK

Uptake rates and specialist advice

Since the RSV vaccine programme commenced in 2024, health officials have stressed the significance of pregnant women getting their jab at the ideal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers nearly 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to maximise the antibodies passed to their babies via the placenta.

The guidance from public health bodies remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.

Regional disparities in immunisation

Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Certain regions have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to increase awareness and access to the jab. These geographical variations reflect differences across healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data demonstrates robust and reliable protection irrespective of geographical location.

• NHS trusts deploying multiple messaging strategies to reach women during pregnancy
• Geographic variations in vaccination coverage levels throughout England necessitate strategic intervention
• Regional health providers modifying schemes to align with local requirements and situations

Practical implications and parental perspectives

The vaccine’s outstanding effectiveness delivers tangible benefits for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the rollout of this safeguarding intervention, the 80% decrease in admissions represents thousands of infants protected against severe infection. Parents no longer face the upsetting situation of watching their newborns labour to breathe or labour to feed, symptoms that define severe RSV infections. The vaccine has markedly changed the picture of neonatal lung health, offering expectant mothers a preventative option to shield their most vulnerable children during those vital initial period.

For families like that of Malachi, whose severe RSV infection led to devastating brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s advocacy for the jab highlights the transformative consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such serious complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to pregnant women navigating their final trimester, transforming what was once an predictable seasonal threat into a controllable health concern.